Companies

SEED Innovations company Eurox changes name to Avextra 

German-based, vertically integrated cannabis company, Eurox, a SEED Innovations Limited portfolio company, has changed its name to Avextra.

SEED Innovations company Eurox changes name to Avextra 
Home / SEED Innovations company Eurox changes name to Avextra 

German-based, vertically integrated cannabis company, Eurox, a SEED Innovations Limited portfolio company, has changed its name to Avextra.

German-based cannabis extracts manufacturer Avextra Eurox has rebranded to Avextra. The rebrand, the company says, emphasises its clear focus on the highest quality cannabis extracts and its commitment to the development of evidence-based cannabis medicines.

SEED Innovations Ltd is an AIM quoted company investing in fast-growing businesses with a focus on the medical cannabis, health and wellness space. It has a 8.85 per cent shareholding in Avextra.

Read more: Eurox begins sale of cannabis products in Germany

Avextra provides SEED with direct access into Germany, the largest cannabis market in Europe today. The vertically integrated production capabilities of Avextra cover cultivation in its Portuguese facility, to manufacturing in Germany thanks to an exclusive, long-term manufacturing agreement in place with an EU GMP certified German pharmaceutical company.

The company began sales of its cannabis products in Germany in November 2021, and in June 2022, raised €4.4, in funding, with Portugal-based Iberis Capital becoming a new institutional investor – its first investment in medical cannabis. 

Avextra (Eurox) emphasised at the time that the development underscored its commitment to its investment in Portugal as a botanical and pharmaceutical research and innovation centre in Europe.

Avextra will be exhibiting at the Expopharm Pharmacists Congress in Munich from 14-17 September 2022.

[activecampaign form=31]

Topicscannabis industryeuropemedical cannabis

Stephanie Price

Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine 'Game Theory' focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on "Medical Cannabis Explained".

More from Stephanie

Spotted an error, or have a tip? Contact the newsroom.

Up next · Companies

Helius Therapeutics to Supply New Phase 2 Cannabis Sleep Trial

Ben Stevens · 20 October 2026

More